Complement C1s

Complement C1s Informations sur la molécule

Nom anglais	Complement C1s	Nombre de médicaments commercialisés	4
Nombre de médicaments cliniques	5	Alias de la cible	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Phase de R&D la plus avancée	Approved

Nom anglais	Complement C1s
Alias de la cible	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Nombre de médicaments commercialisés	4
Nombre de médicaments cliniques	5
Phase de R&D la plus avancée	Approved

Complement C1s Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (1)Cynomolgus (1)
Étiquette
His Tag (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
COS-H52H3	Human	HEK293	Human Complement C1s Protein, His Tag, low endotoxin (MALS verified)				Ajouter au panier
COS-C52H3	Cynomolgus	HEK293	Cynomolgus Complement C1s Protein, His Tag (MALS verified)				Ajouter au panier

Quantité totale2

Complement C1sContexte de la molécule

This gene encodes a serine protease, which is a major constituent of the human complement subcomponent C1. C1s associates with two other complement components C1r and C1q in order to yield the first component of the serum complement system. Defects in this gene are the cause of selective C1s deficiency.

Complement C1sAlias de la molécule

EDSPD2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Complement-C1 inhibitor protein (Octapharma)		Phase 3 Clinical	Octapharma	Angioedemas, Hereditary	Details
Riliprubart	BIVV-020; SAR-445088; TNT-020	Phase 3 Clinical	True North Therapeutics	Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic	Details
C1 esterase inhibitor (Boya Bio-Pharmaceutical)		Phase 3 Clinical	Boya Bio-Pharmaceutical Group Co Ltd	Angioedemas, Hereditary	Details
Claseprubart	DNTH103; DNTH-103	Phase 3 Clinical	Dianthus Therapeutics Inc	Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Details
C1 esterase inhibitor (Chengdu Institute of Biological Products)		Phase 1 Clinical	Chengdu Institute Of Biological Products Co Ltd	Angioedemas, Hereditary	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Conestat alfa	rhC1-INH	Approved	Pharming Group Nv	Rhucin, Esterasine, Ruconest	EU	Angioedemas, Hereditary	Pharming Group Nv	2010-10-28	Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency	Details
Sutimlimab	BIVV-009; TNT-009	Approved	True North Therapeutics	ENJAYMO	United States	Anemia, Hemolytic, Autoimmune	Recordati Rare Diseases Inc	2022-02-04	Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic	Details
Complement C1 inhibitor protein (Shire ViroPharma)	C1 INH-nf; C1-INH; SHP-616	Approved	Sanquin Plasma Products Bv	Cinryze, Cetor	United States	Angioedemas, Hereditary	null	2008-10-10	Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation	Details
C1 esterase inhibitor (Human, CSL Behring)	BI-3.012; CSL-830; CSL-842; CE-1145	Approved	Csl Behring Llc	Berinert, Haegarda, Berinert 2000	Japan	Angioedemas, Hereditary	Csl Behring Llc	1990-06-29	Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation	Details